Search

everythinglearnresearchcommunity

for

Search:↓

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

Bicalutamide may be a promising alternative treatment for female pattern hair loss.

Bicalutamide may effectively treat female pattern hair loss with minimal side effects.

Bicalutamide may help treat female pattern hair loss.

Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

Bicalutamide shows promise for treating female hair loss.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.

Oral bicalutamide is safe and effective for female hair loss.

Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.

Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.

The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.

Bicalutamide improves hair density in women safely.

Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.

The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.